Tango Therapeutics, Inc. (TNGX)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 54 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Tango Therapeutics’ preliminary results for the second fiscal quarter of 2026, reported August 10, showed a wider loss and EPS that trailed consensus, with EPS of $-0.37 trailing the $-0.32 estimate (-17%) and down from $-0.35 a year ago. Net income was a loss of roughly $55.3 million, down 42.4% year over year from a loss of about $38.9 million, alongside an operating loss of about $59.8 million. The company generated negative operating cash flow of roughly $38.9 million in the quarter. For the next period, consensus calls for EPS of $-0.34 on revenue of $3.3 million.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing precision cancer medicines around defined genetic vulnerabilities. Trading as TNGX, it focuses on oncology drug candidates for tumor types selected by specific mutations and alterations, and it operates as a small-cap therapeutic developer in the healthcare sector.
Today's Snapshot
TNGX closed 5.7% higher at 24.00.
Trading Volume
Above 10d avg 2.2M
4.6M
vs S&P 500 Today
Strong Outperformance
+6.21%
Updated: September 10, 2026 at 12:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$19.59 - $25.46Sell
- RSI (14)45.87Neutral
- Stochastic %K (14, 3, 3)26.74Neutral
- MACD Level (12, 26)-1.08Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.